We are excited to share the results from Cardiol Therapeutics’ MAvERIC-Pilot clinical trial, which were recently presented at the American Heart Association Scientific Sessions in November. This trial focused on evaluating the efficacy of CardiolRxâ„¢ in treating patients with symptomatic recurrent pericarditis.
The findings reveal significant reductions in pericarditis pain and inflammation, maintained over a 26-week period. Patients experienced fewer episodes of pericarditis per year, showcasing the potential of CardiolRxâ„¢ to provide lasting relief. These encouraging results set the stage for upcoming Phase II/III and Phase III trials, aimed at preventing the recurrence of pericarditis.
We invite you to explore the full details of this groundbreaking research in the attached PDF.
Cardiol Therapeutics Announces MAvERIC Pilot Results Presented at AHA Scientific Sessions
